RIGL vs TROW · P/E 9.1, rev $179.3M vs P/E 12, rev $7.09B
Rigel Pharmaceuticals Inc (RIGL) versus T. Rowe Price Group Inc (TROW) — a side-by-side from cached financials, not a winner call.
Rigel Pharmaceuticals Inc (RIGL) is a biotechnology company listed on US.
T. Rowe Price Group Inc (TROW) is a asset management company listed on NASDAQ.
Latest reported RIGL revenue for 2024-12-31 was $179.3M. Net income was $17.5M. Revenue was up 53.4% from 2023-12-31 to 2024-12-31. RIGL currently screens at market cap $338.3M and trailing P/E 9.1.
Latest reported TROW revenue for 2024-12-31 was $7.09B. Net income was $2.14B. Revenue was up 9.8% from 2023-12-31 to 2024-12-31. TROW currently screens at market cap $23.17B and trailing P/E 11.6.
RIGL currently screens at market cap $338.3M and trailing P/E 9.1. TROW currently screens at market cap $23.17B and trailing P/E 11.6.
Not investment advice. Open the RIGL and TROW stock pages for the full models.
Not investment advice.